BioXcel Therapeutics (BTAI) Reports Q2 Loss of $1.06/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioXcel Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 14, 2020 7:00 AM EDTSERENITY I & II Phase 3 trials of BXCL501 achieved all primary and secondary endpoints; New Drug Application (NDA) submission to U.S. Food and Drug Administration (FDA) planned for Q1 2021
Initiating the third dose cohort, 90 mcg, of the TRANQUILITY trial in elderly dementia patients
Initiated a separate efficacy cohort in the Phase 2 trial of BXCL701 in combination with pembrolizumab (KEYTRUDA®) to include patients with castrate-resistant prostate cancer (CRPC)
Strengthened balance sheet through follow-on offering raising approximately $200 million in gross proceeds
Company... More
